ОбзорГрафикНовостиTraderScreen

JP Morgan Knock-Out REGN/  DE000JQ63937  /

EUWAX
08.11.2024  21:58:20 Изменение+0.040 Бид22:00:30 Предложение22:00:30 Базовый актив Цена исполнения Дата истечения Тип опциона
0.930EUR +4.49% -
Величина цены спроса: -		 -
Величина цены предложения: -		 Regeneron Pharmaceut... 733.0997 - 31.12.2078 Call
GlobeNewswire 26.08 Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...
GlobeNewswire 26.08 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire 21.08 Regeneron Provides Update on Biologics License Application for Linvoseltamab
GlobeNewswire 07.08 Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
GlobeNewswire 01.08 Regeneron Reports Second Quarter 2024 Financial and Operating Results
GlobeNewswire 31.07 Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
GlobeNewswire 03.07 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...
GlobeNewswire 28.06 Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...
GlobeNewswire 27.06 Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...
GlobeNewswire 26.06 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
GlobeNewswire 16.06 Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...
GlobeNewswire 11.06 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire 31.05 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire 31.05 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire 23.05 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
GlobeNewswire 20.05 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire 17.05 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...
GlobeNewswire 13.05 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire 08.05 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire 06.05 Regeneron Announces Investor Conference Presentations
GlobeNewswire 02.05 Regeneron Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire 29.04 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire 25.04 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire 24.04 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...
GlobeNewswire 22.04 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...